The Interventional Pharmacoeconomic Toolbox Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Peter Clark, MA, MD, FRCP: A Payer Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opening Session Panel Discussion

Apr

Today In Oncology

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Peter Clark, MA, MD, FRCP: A Payer Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opening Session Panel Discussion

James P. Allison, PhD, Honored With the 2026 AACR Award for Lifetime Achievement in Cancer Research

Electroacupuncture Relieves Cognitive Psychological Symptoms in Breast Cancer Survivors in Pilot Study

Elinzanetant May Reduce Side Effects of Endocrine Therapy Among Patients With Breast Cancer

POSITIVE Trial Update: Oncologic Outcomes Maintained After Pausing Endocrine Therapy for Pregnancy

Analysis of Constitutional Cancer Predisposition Gene Variants in Nearly 15,000 Patients